Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 2/20 | 0.41 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311193 | 0.89 | DOT1L (0.38) | TRDMT1 | |
| SCHEMBL21311210 | 0.84 | — | — | |
| SCHEMBL21311195 | 0.79 | EGFR (0.44) | CARM1 | |
| SCHEMBL21311194 | 0.78 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBSLC28A2 | |
| SCHEMBL20096931 | 0.78 | TRDMT1 (0.61) | TRDMT1ATMCARM1 | |
| SCHEMBL21311217 | 0.76 | ADORA2A (0.47) | PI4KAPI4K2BPI4K2API4KBSLC28A2 | |
| SCHEMBL20097184 | 0.75 | — | — | |
| SCHEMBL23025515 | 0.74 | ADORA3 (0.53) | PI4KAPI4K2BPI4K2API4KBSLC28A2 | |
| SCHEMBL21311216 | 0.74 | ADORA2A (0.47) | PI4KAPI4K2BPI4K2API4KBSLC28A2 | |
| SCHEMBL25521510 | 0.74 | ADORA3 (0.53) | PI4KAPI4K2BPI4K2API4KBSLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | CHKA 2475/4885TRDMT1 28/4885PI4KA 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.